Faruqi and Faruqui, LLP Logo
Share this page

Rockwell Medical, Inc. (RMTI)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Rockwell Medical, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Rockwell Medical, Inc. (“Rockwell” or the “Company”) (NASDAQ: RMTI) of the September 25, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Rockwell stock or options between March 16, 2018 and June 26, 2018 and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of all those who purchased Rockwell securities between March 16, 2018 and June 26, 2018 (the “Class Period”).  The case, Too v. Rockwell Medical, Inc. et al, No. 18-cv-04253 was filed on July 27, 2018, and has been assigned to Judge Allyne R. Ross.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) Rockwell was aware that the Centers for Medicare and Medicaid Services (“CMS”) would not pursue Rockwell’s proposal for separate reimbursement for Triferic, the Company’s lead branded drug, which serves as an iron maintenance therapy for patients undergoing hemodialysis treatment; (2) the estimated reserves in the first quarter 2018 10-Q were misstated; (3) a material weakness in Rockwell’s internal controls over financial reporting rendered them ineffective; and (4) Robert Chioini, the Company’s President and Chief Executive Officer, withheld material information from Rockwell’s auditor, counsel, and certain directors.

Specifically, aftermarket on May 22, 2018, Rockwell announced that Robert Chioini had been terminated effective immediately. On May 23, 2018, NASDAQ announced that “trading in the company’s stock had been halted . . . for ‘news pending’ at a last sale price of $5.94.”

On this news, the Company’s share price fell from $5.94 on May 22, 2018 to $5.57 when it resumed trading on May 29, 2018—a $0.37 or 6.23% drop.

Then, premarket on June 27, 2018, Rockwell filed a Form 8-K announcing the resignation of its auditor. According to the auditor, Rockwell misrepresented the likelihood that its proposal to have Triferic gain separate reimbursement status with the CMS would be accepted. This misinformation meant that the estimated reserves in Rockwell’s first quarter 2018 10-Q were misstated because CMS had decided not to pursue the Company’s proposal, and, consequently, that a material weakness existed in Rockwell’s internal controls over financial reporting.

On this news, the Company’s share price fell from $5.26 on June 26, 2018 to $4.41 per share on June 28, 2018—a $0.85 or 16.16% drop over two trading days.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Rockwell Medical, Inc. (RMTI)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 07/30/2018

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.